Bimzelx five year data

[Caroline]

UCB have released Bimzelx (bimekizumab) 5 year data.

•    
  
• High response rates in patients at risk of psoriatic arthritis at three years: Data showed 68.7–71.6% of PSO patients at risk of developing psoriatic arthritis (PsA) achieved complete skin clearance, generally consistent with the overall treated group. Similar results were seen in all patients with PSO, including those with PsA at baseline
     
  

Bimzelx (bimekizumab)

Very good results.. AND long term.

I don’t get the meaning of above line.

I have read it several times, but to me it is non-information.

High response rates in patients at risk of Psoriatic Arthritis……. That is 30% of the whole pso population. But how do they know which ones are at risk….????
Only that knowledge is already gold… but I don’t think they know that.

So the statement is irrelevant.